Option Care HealthNASDAQ: OPCH

The medical field is a non-negotiable aspect of society. Advanced healthcare is required to combat existing diseases and protect ourselves from new ones.

Option Care (OPCH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Option Care Health Inc. will be attending the following investor conferences in the near future.

Option Care (OPCH) could see an increase in its stock price due to increasing confidence in its earnings potential, as indicated by its upgrade to a Zacks Rank #2 (Buy).

Option Care Health, Inc. (OPCH) Q4 2023 Earnings Call Transcript

Option Care (OPCH) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of $0.29 per share. This compares to earnings of $0.26 per share a year ago.

Option Care (OPCH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Option Care Health gives investors exposure to two healthcare megatrends: (i) the shift to healthcare delivery in the home; and (ii) the development of specialty pharmaceuticals. I believe OPCH holds a competitive moat, not only as the largest infusion provider in the US, but also due to its business model (predictable revenue and sticky client/customer base). I explain the street is highly conservative and project a ~150bps upside to FY24E EBITDA, and apply a ~15x multiple to that projection to arrive at my $38 2024 PT.

Option Care Health easily beat analysts' models for revenue and earnings in the third quarter of 2023. The company also raised its full-year outlook -- but not enough to live up to Wall Street's already high expectations.